research Dutasteride for the treatment of benign prostatic hyperplasia
Dutasteride effectively treats benign prostatic hyperplasia but isn't approved for preventing prostate cancer.
Search
for
Sort by
Research
180-210 / 1000+ results
research The effects of lovastatin on conventional medical treatment of lower urinary tract symptoms with finasteride
Lovastatin doesn't improve lower urinary tract symptoms treatment.
research Dihydrotestosteron und die Rolle der 5α-Reduktasehemmer bei der benignen Prostatahyperplasie
A stronger dual 5α-reductase inhibitor could improve treatment for benign prostatic hyperplasia by further reducing DHT levels.
research Novel tip-loaded dissolving and implantable microneedle array patches for sustained release of finasteride
New dissolving and implantable microneedle patches have been created for a long-lasting, non-invasive delivery of the drug finasteride.
research Economic analysis of finasteride: A model-based approach using data from the Proscar long-term efficacy and safety study
Finasteride is a cost-effective option for treating BPH, reducing risk of urinary issues and surgery.
research Finasteride: The First 5α-Reductase Inhibitor
Finasteride treats enlarged prostate and baldness, but may cause limited urinary improvement and sex-related side effects.
research Benign Prostatic Hyperplasia: A Disorder of Androgen Metabolism in the Male
Benign Prostatic Hyperplasia may be caused by changes in how the body processes male hormones.
research A population‐based nested case–control study: the use of 5‐alpha‐reductase inhibitors and the increased risk of osteoporosis diagnosis in patients with benign prostate hyperplasia
Taking finasteride for benign prostate hyperplasia may increase the risk of osteoporosis, especially at higher doses.
research Is COVID-19 a risk factor for progression of benign prostatic hyperplasia and exacerbation of its related symptoms?: a systematic review
COVID-19 might worsen symptoms and progression of benign prostatic hyperplasia, possibly due to inflammation and metabolic disturbances in the prostate gland. More research is needed to confirm this.
research Endocrinology of the Aging Prostate: Current Concepts
Hormones affect prostate health and disease, with certain hormone imbalances linked to prostate cancer and benign prostatic hyperplasia.
research Sexual side effects of 5-α-reductase inhibitors finasteride and dutasteride: A comprehensive review
Finasteride and dutasteride can cause sexual problems like impotence and low libido.
research The pathophysiology of delayed ejaculation
Delayed ejaculation is a complex issue caused by psychological, biological, and lifestyle factors, requiring a holistic treatment approach.
research Alopecia in Epidermolysis Bullosa
The document suggests that certain protein deficiencies and scalp blistering in Epidermolysis Bullosa may cause hair loss.
research Meta-Analysis of Randomized Clinical Trials of Finasteride
Finasteride effectively treats BPH and hair loss but may cause sexual side effects.
research Comparative Study of Therapeutic Effect of Dibenyline, Finasteride, and Combination Drugs for Symptomatic Benign Prostatic Hyperplasia
All treatments helped with prostate symptoms, but the combination of dibenyline and finasteride worked best without extra side effects.
research 5α‐Reductase inhibitors and prostatic disease
5α-Reductase inhibitors can help treat hair loss, acne, and prostate issues by reducing DHT levels.
research Finasteride, not tamsulosin, increases severity of erectile dysfunction and decreases testosterone levels in men with benign prostatic hyperplasia
Finasteride worsens erectile dysfunction and lowers testosterone in men with enlarged prostates, unlike tamsulosin.
research The prostaglandin synthases, COX-2 and L-PGDS, mediate prostate hyperplasia induced by low-dose bisphenol A
Low-dose bisphenol A increases prostate size in rats by affecting certain enzymes.
research Neuropsychological Assessment in Elderly Men with Benign Prostatic Hyperplasia Treated with Dutasteride
Dutasteride does not impair mental function in elderly men with enlarged prostate.
research Finasteride and Erectile Dysfunction in Patients with Benign Prostatic Hyperplasia or Male Androgenetic Alopecia
Finasteride may increase erectile dysfunction risk in patients with benign prostatic hyperplasia.
research Long-term dutasteride therapy in men with benign prostatic hyperplasia alters glucose and lipid profiles and increases severity of erectile dysfunction
Long-term use of dutasteride for enlarged prostate may worsen blood sugar, cholesterol, and erectile dysfunction.
research Corn silk extract improves benign prostatic hyperplasia in experimental rat model
Corn silk extract helps reduce prostate enlargement symptoms.
research Ezetimibe Reduces Enlarged Prostate in an Animal Model of Benign Prostatic Hyperplasia
Ezetimibe effectively reduces prostate size in cases of benign prostatic hyperplasia.
research Comparison of clinical trials with finasteride and dutasteride.
Dutasteride reduces DHT more than finasteride, but both drugs improve BPH symptoms similarly.
research Novel inhibitors of 5α-reductase
New research is needed to create better drugs that block the enzyme responsible for conditions like male baldness and prostate enlargement.
research Synthesis of phenanthridin-3-one derivatives: Non-steroidal inhibitors of steroid 5-α-reductase
New chemicals were made that can block an enzyme linked to hair loss, prostate growth, and acne.
research Efficacy and safety of 5 alpha-reductase inhibitor monotherapy in patients with benign prostatic hyperplasia: A meta-analysis
5 alpha-reductase inhibitors can slightly improve symptoms of enlarged prostate but have a high risk of sexual side effects.
research Benign prostatic hyperplasia and male lower urinary symptoms: A guide for family physicians
Family doctors can manage older men with urinary symptoms using exams, tests, and medications.
research Discovery of a novel hybrid from finasteride and epristeride as 5α-reductase inhibitor
New hybrid compound found to effectively prevent hair loss.
research A regulatory perspective on pharmacokinetic/pharmacodynamic modelling
The document concludes that PK/PD modeling is important for determining the safe and effective dosages of drugs.